What Researchers Did
The authors reviewed published studies on low oxygen in tumours, how it is measured, how patients are chosen for treatments aimed at it, and ways to overcome it during treatment.
What They Found
This review of published studies describes tumour hypoxia as a feature of many solid tumours that decreases the effectiveness of radiation treatment, surgery and some forms of chemotherapy. Approaches to counteract this resistance have been developed, but usually at the cost of increased short- and long-term side-effects. New methods for measuring tumour oxygen have made it possible to establish the prognostic significance of hypoxia. Several genes and proteins involved in the response to hypoxia have been identified as possible candidates for future predictive tests. Some markers and combinations have shown potential benefit and are associated with treatment outcome, but their clinical usefulness needs to be validated in prospective trials.
What This Means for Canadian Patients
For people with solid tumours, the abstract says that measuring how much of a tumour is low in oxygen may help select patients for hypoxia-modifying treatments. The abstract does not describe hyperbaric oxygen therapy, its results, or whether it should be used, so it gives no guidance on HBOT. Patients with questions about their own cancer treatment should speak with their oncology team.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
The abstract describes a review of published studies rather than new patient data, and it states that the predictive markers still need validation in prospective trials before their clinical usefulness is known.